SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Advanced Viral Research CP (ADVR)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Philip Pravda who wrote (654)8/19/1996 4:51:00 PM
From: eddie   of 2281
 
I. DISTRIBUTION AGREEMENTS

The Company has entered into separate agreements with five different
entities (the "Entities"), whereby the Company has granted exclusive
rights to distribute Reticulose in the countries of China, Japan,
Thailand, Singapore, Hong Kong, Taiwan, Malaysia, Mexico, Saudi Arabia,
Argentina, Bolivia, Paraguay, Uruguay, Brazil, Chile, Channel Islands, The
Isle of Man, British West Indies, Jamaica, Haiti, Bermuda, and Belize.
Pursuant to these agreements, distributors are obligated to cause
Reticulose to be approved for commercial sale in such countries and upon
such approval, to purchase from the Company certain minimum quantities of
Reticulose to maintain the exclusive distribution rights. Leonard Cohen, a
former consultant to the Company, has informed the Company that he is an
affiliate of two of these entities.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext